Combinational treatment with microRNA-133b and cetuximab has increased inhibitory effects on the growth and invasion of colorectal cancer cells by regulating EGFR

Molecular Medicine Reports

Volumn 12, Issue 4, 2015, Pages 5407-5414

  Zhou, Jianyu ^a   Lv, Lv ^b   Lin, Changwei ^a   Hu, Gui ^a   Guo, Yihang ^a   Wu, Meirong ^a   Tian, Buning ^a   Li, Xiaorong ^a  

^a THE THIRD XIANGYA HOSPITAL OF CENTRAL SOUTH UNIVERSITY   (China)

^b Department of Emergency ^*  (China)

Author keywords

Cetuximab; Colorectal cancer; Epidermal growth factor receptor; MiR 133b

Indexed keywords

CETUXIMAB; MICRORNA; MICRORNA 133B; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; MIRN133 MICRORNA, HUMAN;

ARTICLE; CANCER CELL; CANCER PATIENT; CANCER TISSUE; CELL GROWTH; CELL INTERACTION; CELL INVASION; COLORECTAL CANCER; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LUCIFERASE ASSAY; QUANTITATIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ANTAGONISTS AND INHIBITORS; CELL CYCLE; CELL MOTION; CELL PROLIFERATION; COLORECTAL TUMOR; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; METABOLISM; PATHOLOGY; RNA INTERFERENCE; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CETUXIMAB; COLORECTAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; MICRORNAS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA INTERFERENCE;

EID: 84940525493     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2015.4046     Document Type: Article

References (25)

1. Asbagh LA, Vazquez I, Vecchione L, et al: The tyrosine phos-phatase PTPRO sensitizes colon cancer cells to anti-EGFR therapy through activation of SRC-mediated EGFR signaling. Oncotarget 5: 10070-10083, 2014
2. Lewis BP, Burge CB and Bartel DP: Conserved seed pairing, often fanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120: 15-20, 2005.
3. Kato M and Slack FJ: microRNAs: small molecules with big roles-C. elegans to human cancer. Biol Cell 100: 71-81, 2008.
4. Jansson MD and Lund AH: MicroRNA and cancer. Mol Oncol 6: 590-610, 2012.
5. Qiu T, Zhou X, Wang J, et al: MiR-145, miR-133a and miR-133b inhibit proliferation, migration, invasion and cell cycle progression via targeting transcription factor Sp1 in gastric cancer. FEBS Lett 588: 1168-1177, 2014.
6. Wen D, Li S, Ji F, et al: miR-133b acts as a tumor suppressor and negatively regulates FGFR1 in gastric cancer. Tumour Biol 34: 793-803, 2013.
7. Zhao Y, Huang J, Zhang L, et al: MiR-133b is frequently decreased in gastric cancer and its overexpression reduces the metastatic potential of gastric cancer cells. BMC Cancer 14: 34, 2014.
8. Zhou Y, Wu D, Tao J, Qu P, Zhou Z and Hou J: MicroRNA-133 inhibits cell proliferation, migration and invasion by targeting epidermal growth factor receptor and its downstream effector proteins in bladder cancer. Scand J Urol 47: 423-432, 2013.
9. Tao J, Wu D, Xu B, et al: microRNA-133 inhibits cell proliferation, migration and invasion in prostate cancer cells by targeting the epidermal growth factor receptor. Oncol Rep 27: 1967-1975, 2012.
10. Liu L, Shao X, Gao W, et al: MicroRNA-133b inhibits the growth of non-small-cell lung cancer by targeting the epidermal growth factor receptor. FEBS J 279: 3800-3812, 2012.
11. Wu J, Yang T, Li X, et al: Alteration of serum miR-206 and miR-133b is associated with lung carcinogenesis induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Toxicol Appl Pharmacol 267: 238-246, 2013.
12. Akcakaya P, Ekelund S, Kolosenko I, et al: miR-185 and miR-133b deregulation is associated with overall survival and metastasis in colorectal cancer. Int J Oncol 39: 311-318, 2011.
13. Davis NM, Sokolosky M, Stadelman K, et al: Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention. Oncotarget 5: 4603-4650, 2014
14. Centuori SM and Martinez JD: Differential regulation of EGFR-MAPK signaling by deoxycholic acid (DCA) and ursodeoxycholic acid (UDCA) in colon cancer. Dig Dis Sci 59: 2367-2380, 2014
15. Wang F, Xiao W, Sun J, Han D and Zhu Y: MiRNA-181c inhibits EGFR-signaling-dependent MMP9 activation via suppressing Akt phosphorylation in glioblastoma. Tumour Biol 35: 8653-8658, 2014
16. Mlcochova J, Faltejskova P, Nemecek R, Svoboda M and Slaby O: MicroRNAs targeting EGFR signalling pathway in colorectal cancer. J Cancer Res Clin Oncol 139: 1615-1624, 2013.
17. Garofalo M, Romano G, Di Leva G, et al: EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers. Nat Med 18: 74-82, 2011.
18. Gu YF, Zhang H, Su D, et al: miR-30b and miR-30c expression predicted response to tyrosine kinase inhibitors as first line treatment in non-small cell lung cancer. Chin Med J (Engl) 126: 4435-4439, 2013.
19. Zhou YM, Liu J and Sun W: MiR-130a overcomes geftinib resistance by targeting met in non-small cell lung cancer cell lines. Asian Pac J Cancer Prev 15: 1391-1396, 2014.
20. Ragusa M, Majorana A, Statello L, et al: Specifc alterations of microRNA transcriptome and global network structure in colorectal carcinoma after cetuximab treatment. Mol Cancer Ther 9: 3396-3409, 2010.
21. Calin GA and Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer 6: 857-866, 2006.
22. Nielsen S, Scheele C, Yfanti C, et al: Muscle specific microRNAs are regulated by endurance exercise in human skeletal muscle. J Physiol 588: 4029-4037, 2010.
23. Novello C, Pazzaglia L, Cingolani C, et al: miRNA expression profile in human osteosarcoma: role of miR-1 and miR-133b in proliferation and cell cycle control. Int J Oncol 42: 667-675, 2013.
24. Kano M, Seki N, Kikkawa N, et al: miR-145, miR-133a and miR-133b: Tumor-suppressive miRNAs target FSCN1 in esophageal squamous cell carcinoma. Int J Cancer 127: 2804-2814, 2010.
25. Qin W, Dong P, Ma C, et al: MicroRNA-133b is a key promoter of cervical carcinoma development through the activation of the ERK and AKT1 pathways. Oncogene 31: 4067-4075, 2012.